Diagonal Bio AB publish – White paper

Diagonal Bio publishes its latest white paper describing the technology and specifications of its the LAMPlify® and Panviral® platforms for pathogen detection in a user-centric, 8-parallel test format. The platform technology taps into the ultra-fast speed and convenience of the Loop-mediated Isothermal Amplification (LAMP), and the specificity and robustness of Electrochemical detection. As a part of Diagnostic Performance Evaluation of the LAMPlify® system, over 500 tests have been assessed with 7 different genetic markers, from 6 different pathogens. The technology shows impressive overall Accuracy of 99.6 %, Sensitivity of 100 %, and Specificity of 99.5 %.

 

“The cumulative analysis we have recently performed over several months of work by our team, in addition to the work with biological samples, clearly demonstrates the unparalleled and unprecedented performance of our ultra-rapid yet highly accurate nucleic acid amplification platforms”, says Roman Lyttleton, Technical Product Development Leader at Diagonal Bio.

 

” If it’s time critical to get diagnostic results, even from multiple pathogens, Diagonal Bio’ technology shows to be an attractive solution”, says Karin Wehlin, CEO Diagonal Bio.

 

For more information about the Company, please contact:

Karin Wehlin, CEO
Phone: +46 (0)70 305 24 88
E-mail: kw@diagonalbio.com
www.diagonalbio.com

Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se

About Diagonal Bio

Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionizing global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio’s patented technology can also be used for the less regulated market segments via LAMPlify®.